Skip to main content

What the FDA labels say about taking them together

Carbamazepine and palbociclib

Palbociclib's FDA label of July 2, 2026 names carbamazepine in its drug interactions section; the carbamazepine labels PlainMeds reads (3) do not name palbociclib. The palbociclib label: “Avoid concomitant use of strong CYP3A inducers.”

Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the carbamazepine label say about palbociclib?

Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name palbociclib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed

What does the palbociclib label say about carbamazepine?

Palbociclib label, drug interactions

Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine, enzalutamide, and St John's Wort) [see Clinical Pharmacology (12.3) ].

Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

42Carbamazepine generic labelers
0Palbociclib generic labelers
CarbamazepinePalbociclib
Labeled forBipolar disorder, Seizures and epilepsyBreast cancer
Boxed warningYesNo
Pharmacy cost (NADAC)$0.119 per tablet 200 mg tabletn/a
Shortage nowA presentation being discontinuedA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?